PAR-1 is the activator of the innate immune system, which can be administered systemically or locally. It is readily soluble in water and physiological solutions, and has high molar activity with the treatment dose for humans being 20μg. Its manufacturing involves proprietary know-how and other intellectual property controlled by Pattern.
Infectious Disease Applications: PAR-1 is an efficacious activator of antiviral and antibacterial immune responses, and there is substantial human data supporting the efficacy of PAR-1 against infections caused by a variety of viruses (e.g., HPV, HSV, CMV), bacteria (e.g., E. coli, Salmonella, Staphylococcus, Chlamydia) and protozoa (e.g. Trichomonas vaginalis).
Cancer Applications: PAR-1 activated immune cells are tumoricidal and, given they sit at the top of the immune response stack, they also trigger subsequent adaptive immune responses and enhance other immuno-oncology therapeutics such as checkpoint inhibitors. There is substantial data from studies supporting the efficacy of PAR-1 against a variety of cancers including prostate cancer (human data), renal cancer (human data), breast cancer (preclinical) and lung cancer (in vitro).
Other Applications: PAR-1 is also an effective vaccine carrier and an ex vivo activator of innate immune cells (DCs etc.)
Collaborations: Pattern collaborates closely with leading US and Canadian research institutions on its preclinical and clinical development programs.